TrialReader


Dexamethasone at Night vs at Induction on PONV After Laparoscopic Cholecystectomy

NCT05998317 — Phase 2 / Phase 3, Completed, 60 participants, Mansoura University

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Dexamethasone At-induction vs At-night to Prevent Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy: A Protocol for Randomized Clinical Trial

RegistryNCT05998317
StatusCompleted
PhasePhase 2 / Phase 3
Study typeInterventional; randomized, parallel, masking: triple, prevention
Enrollment60 (Actual)
SponsorMansoura University (Other)
ConditionsPostoperative Nausea and Vomiting, Postoperative Pain, Laparoscopic Cholecystectomy
InterventionsAt-night Dexamethasone, At-induction Dexamethasone (Drug)
Datesstart 2023-10-08, primary completion 2023-11-15, completion 2023-11-20, first posted 2023-08-18, last updated 2024-01-25
Locations1 site in Egypt

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Postoperative Nausea and Vomiting All trials for Postoperative Pain All trials of At-night Dexamethasone All trials of At-induction Dexamethasone

-Summary

Since the peak effect of the dexamethasone is delayed to 12-16 hours after iv administration, we designed this study to investigate the effect of administering dexamethasone at-night before surgery versus at-induction (the standard timing) in prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy.

A pilot randomized controlled study (60 cases) will be started to explore the potential difference, ensure correct and rigorous data collection, and calculate the sample size for a larger pragmatic trial.

Expand all sections  ·  Collapse all

+Detailed description

Background:

Postoperative nausea and vomiting (PONV) are common complications after laparoscopic cholecystectomy. The aim of this study is to evaluate the efficacy of administration of prophylactic dexamethasone 12-hours prior to induction of anesthesia in preventing PONV after elective laparoscopic cholecystectomy, as it reaches its peak effect at 2-12 hours and lasts for 72 hours after intravenous (iv) administration.

Methods:

This is a parallel two-arm, randomized (1:1), double-blind, controlled, single-center trial. Adults (≥18 years) with American Society of Anesthesiology (ASA) physical status I-III scheduled for elective laparoscopic cholecystectomy will be eligible for inclusion. The participants will be randomized to receive either 8 mg IV Dexamethasone at time of induction of anesthesia or 8 mg IV Dexamethasone at 12 hours prior to induction of anesthesia. The primary outcome will be the incidence of postoperative nausea and vomiting. A total of 60 patients will be recruited as a pilot study.

+Arms and interventions

ArmTypeInterventionsDescription
At-night dexamethasoneExperimentalDrug: At-night DexamethasonePatients in the intervention group will receive intravenous 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
At-induction dexamethasoneActive comparatorDrug: At-induction DexamethasonePatients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
  • At-night Dexamethasone (Drug): Patients in the intervention group will receive intravenous 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
  • At-induction Dexamethasone (Drug): Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.

+Outcome measures

Primary outcomes

  • postoperative nausea or vomiting (PONV) [24 hours after surgery]: incidence of PONV (binary outcome as yes/No)

Secondary outcomes

  • The need for rescue antiemetic [24 hours after surgery]: Dichotomous yes/no outcome
  • The need for rescue analgesia [24 hours after surgery]: Dichotomous yes/no outcome
  • Postoperative Care Unit (PACU) and Early PONV [within 6 hours after surgery]: Dichotomous yes/no outcome
  • Late PONV [6-24 hours after surgery]: Dichotomous yes/no outcome
  • Visual Analogue Scale (VAS) [at the time of discharge from PACU (usually at 2 hours after surgery)]: VAS as a scale 0 - 10
  • Visual Analogue Scale (VAS) [at the time of discharge from hospital (usually 24 hours after surgery)]: VAS as a scale 0 - 10
  • Postoperative quality of recovery (QoR) [24 hours after surgery]: QoR-15 questionnaire (doi: https://doi.org/10.1097/ALN.0b013e318289b84b)
  • Post-Discharge Nausea and Vomiting (PDNV) [at 72 hours after surgery]: evaluated by telephone by Dichotomous yes/no outcome

Other outcomes

  • Surgical Site Infection [at follow-up (usually at 7 days after surgery)]: infection as defined by the surgeon) at the trocar's or the drainage tube sites.
  • Itching or burning sensation [during injection of the dexamethasone]: as described by the patient as dichotomous outcome yes/no outcome

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* all consecutive adults (older than 18 years) with ASA physical status I-III undergoing elective laparoscopic cholecystectomy surgery at gastrointestinal surgery center.

Exclusion Criteria:

* patient refusal
* use of steroids or antiemetic agents within 1 week of surgery
* chronic opioid therapy
* history of allergy to any study medications
* serum creatinine > 1.4 mg/dl
* liver enzymes more than triple normal limits
* pregnancy
* psychiatric or neurologic diseases or socioeconomic status that would hinder postoperative quality of recovery questionnaire
* Patients whose laparoscopic surgery is converted to open surgery after enrollment will be excluded.

+Locations (1)

FacilityCityCountryStatus
Faculty of MedicineAl Mansurah, AldakahliaEgypt

+Investigators

My Notes